Articles On Neuren Pharmaceuticals (ASX:NEU)

The market may be nearing a record high, but that doesn't mean there aren't big potential gains to be made. For example, the ASX 200 share in this article, which is swimming in cash, has been tipped rise very strongly from current levels. W...

The S&P/ASX 200 Index (ASX: XJO) enjoyed an enthusiastic end to the trading week this Friday, giving investors a tangible boost as we head into the weekend. After spending all day in positi...

Highlights ASX gains on Fed rate cuts and China's potential stimulus. Life360 and Commonwealth Bank hit new highs. Mining and tech stocks lead the rally, with notable rises in iron ore and gold. Australian shares rallied on Friday...

Highlights  S&P/ASX 200 rises on global rate cuts and China stimulus hopes.   Tech and banking stocks soar; energy sector lags.    Block Inc drops despite strong profits. The Australian share market showed positive momentum i...

ASX rallies broadly as tech stocks lead Commonwealth Bank hits record, Neuren jumps Asian markets rise, China stimulus eyed   The ASX was riding the coattails of a strong Wall Street session, with tech stocks leading the charge.  At the c...

The S&P/ASX 200 Index (ASX: XJO) is having a great finish to the week. In afternoon trade, the benchmark index is up 0.9% to 8,299.4 points. Four ASX shares that are rising more than most are listed below. Here's why they are charging...

It was a wild session for the S&P/ASX 200 Index (ASX: XJO) this Thursday as investors continued to digest the impact of this week's American elections. After several stints in both positive...

ASX slipped after early gains, then finished strongly  Energy sector helped offset losses; Quickstep, Sigma Healthcare turned heads Wall Street rallied to record highs after Trump’s win   The ASX swung from gains, to losses at lunchtime,...

Highlights  ASX gains slightly, led by energy and mining sectors on China stimulus hopes. Banking sector mixed as rate-sensitive stocks face pressure. Sigma Healthcare and Neuren post significant gains following positive development...

The S&P/ASX 200 Index (ASX: XJO) has failed to follow Wall Street's stunning lead and has dropped into the red. In afternoon trade, the benchmark index is down 0.2% to 8,182.9 points. Four ASX shares that are not letting that hold them...

Highlights  ASX edges lower due to declines in property sector despite gains in other sectors. National Australia Bank posts mixed results, while big miners show slight advances. Sigma Healthcare soars on regulatory approval for a key...

Highlights Australian shares dip as miners and banks retreat post-U.S. election. Notable drops in major banks and gold stocks impact ASX performance.  Positive gains for Sigma Healthcare, Steadfast, and Neuren Pharmaceuticals. Au...

Having pocketed a US$50 million share of an FDA priority review voucher, Neuren reports bumper results. ACCC says ‘no probs’ to Sigma-Chemist Warehouse union  The Trump Ascendency Mark Two is a double-edged sword for the healthcare sector...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin National Australia Bank ((NAB)) has released an FY24 result largely in line with ana...

The ASX200 has been up 0.83% at 8199 points. Counting in the US election continues and markets are eagerly watching the results trickle in and are reacting accordingly. All sectors have gained ground and the IT sector has been the bes...

Neuren Pharmaceuticals (ASX: NEU), a Melbourne-based biotech that is developing therapies for neurodevelopmental disorders in early childhood, has scored a cash windfall from the US$150 million ($229 million) sale of a Rare Paediatric Disea...

ASX healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) has surged in early trade on Wednesday after a company update. Shares in the biopharma company currently fetch $12.95 apiece, nearly 6% higher on the day after it announced it w...

Neuren Pharmaceuticals (ASX:NEU) is set to receive a substantial payout following the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) by its US-based partner, Acadia Pharmaceuticals (NASDAQ: ACAD), for $US150m. Under the agre...

Are you on the hunt for big returns to supercharge your portfolio? If you are, then it could pay to listen to what analysts are saying about the ASX 200 growth stocks listed below. Here's why analysts are feeling bullish about these stocks...

Looking for big returns to supercharge your investment portfolio? If you are, it could be worth checking out the two ASX 200 growth shares listed below that have been tipped to rise strongly from current levels. Here's what analysts are say...

What’s in a name? Not much, according to the CEO of the now cashed-up Percheron, Dr James Garner. Formerly known as Antisense Therapeutics, the rare disease specialist changed its name to Percheron in January. Percheron means ‘draught horse...

The ASX200 closed up around 0.9% at 8,355 points after hitting a new record of 8,384 points just before September jobs data was released this morning. The better than expected unemployment rate of 4.1% saw markets reduce the odds of an R...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.7% to 8,345.3 points. Four ASX shares that are rising more than most today are listed below....

The Australian share market is rebounding nicely on Thursday following a solid session on Wall Street overnight. Two ASX 200 shares that are contributing are listed below. Here's why they are pushing higher today: Neuren Pharmaceuticals Lt...

Nyrada to launch phase I first-in-human trial after passing preclinical safety studies Neuren Pharmaceuticals ‘mini me’ Percheron seeks funds for rare disease program Another win for Pro Medicus, this time locally   Nyrada (ASX:NYR) share...

  Jon Pilcher – Managing Director & CEO – Neuren Pharmaceuticals Limited (ASX:NEU) is developing new therapies for highly debilitating neurodevelopmental disorders that emerge in early childhood.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is fighting hard to get into positive territory but has fallen a touch short. The benchmark index is down slightly to 8,203.4 points. Four ASX shares that are falling more than most...

The ASX200 has been up around 0.6% of a percent at 8,198 points in early afternoon trade. The labour day holiday in some states has seen the bourse trading in lower volumes, as investors continue to digest the unfolding conflict in the M...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.5% to 8,188.4 points. Four ASX shares that are rising more than most today are listed below....

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are having a strong start to the week. In morning trade, the ASX 200 healthcare stock is up over 4% to $14.63. Why is this ASX 200 healthcare stock charging higher? The catalyst for this gain has...

Neuren Pharmaceuticals (ASX:NEU) has said it’s received a “positive” response from the FDA regarding a potential approval for its Phase 3 trial to treat children with Phelan-McDermid Syndrome (PMS.) Using Neuren’s in-house drug candidate...

If you are looking for some new additions to your portfolio in October, then the ASX shares listed below could be worth a closer look. They have both been named as favoured shares by Bell Potter for the month ahead. The broker notes that...

It was a bouncy, yet overall positive day for ASX shares this Friday to end the trading week. By the time trading wrapped by, the S&P/ASX 200 Index (ASX: XJO) had inched 0.1% higher, leaving...

Stockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event highlighted some of ASX’s leading and up-and-coming biotech and life sciences companies Imricor Medical Systems, Race Oncology, Clarity Pha...

The S&P/ASX 200 Index (ASX: XJO) may be at a record high, but that doesn't mean there aren't any great value shares out there. For example, the two ASX 200 shares listed below have been named as strong buys by brokers and tipped to ris...

When I last covered ImpediMed (ASX:IPD) in May last year, I opined that the time-honoured way of lifting team performance was to replace the coach – a ploy that works about as often as it doesn’t. Back then, Rick Valencia had just replaced...

Are you wanting big returns for your portfolio? Then look no further! That's because the ASX 200 shares listed below have been named as buys and tipped to rise by ~40%+ from current levels. Here's what analysts are predicting from them: Ne...

The S&P/ASX 200 Index (ASX: XJO) ended the trading week on a high this Friday. Literally so, with the index once again resetting its intraday trading re...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

4DMedical could replicate Pro Medicus’ US success Its new tech could revolutionise lung disease diagnostics  Potential Philips deal drives optimism for 4DX Stockhead’s markets guru Eddy Sunarto brings you the latest updates from leading A...

Dimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involved Dimerix is in phase III trials to treat a rare kidney condition Following promising interim analysis, further results are expected in mid...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck Welcome to the FNArena Corporate Results Monitor. Today's Reports:...

ASX healthcare stocks showed mixed results following the release of their most recent financials on Tuesday. Three companies in particular stand out, with two finishing in the green and one in the red. Integral Diagnostics Ltd (ASX: I...

You'll find that not everyone's definition of top ASX stocks is the same. Some investors prefer lower-risk blue-chip stocks, while others are willing to take a punt on higher-risk small-cap growth shares. And, of course, passive income inve...

ASX health stocks rise 0.8% past five days as broader market lifts 3.7%  Morgans says ProMedicus ‘produced yet another record result’ with net profit of $82.8m in FY24  CSL falls on FY24 results but Morgans still bullish on ASX’s largest h...

Neurotech to secure one or more strategic partnerships for NTI164 in the US, Europe and Asia Partnerships aim to support clinical, regulatory development, manufacturing and future market launches of NTI164 Neurotech to pursue multiple regi...

The Australian Securities Exchange (ASX) has started this week on a much more positive note compared to last week as investors eagerly await earnings from some of the ASX’s biggest companies.  The S&P/ASX200 rallied 58.1 points to 7,...

The ASX200 closed up 1.25% at 7777.7 points, completing the second green session in a row. It has been a volatile time, and the market has finished the week by clawing back some, but not all, losses from the previous 5 sessions. China...

While the S&P/ASX 200 Index (ASX: XJO) is enjoying a strong session on Friday, up 1.45% to 7,792.6 points, several ASX shares are struggling to keep pace. Here’s a look at four companies experiencing declines today and the reasons behin...

The Australian Securities Exchange (ASX) has rounded out a volatile week in the positive, with the S&P/ASX200 advancing 95.70 points, or 1.3%, to 7,777.70 on Friday (9 August). The index rose above its 125-day moving average and all...